V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004719 | 310002093 | null | 70.3 | Curative (C) | 2013-09-16 | 2013-09-20 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | N | N | 310023335 | ICON8B TRIAL |
| 310004720 | 310006889 | 1.73 | null | null | 2017-03-30 | 2017-04-10 | CYCLOPHOSPHAMIDE | 2 | N | 310023341 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 310004721 | 310006889 | null | 53.5 | Palliative (P) | 2014-09-30 | 2014-10-03 | Pazopanib | N | null | 310023341 | INTERFERON |
| 310004722 | 310006889 | 1.69 | 58.8 | Curative (C) | 2013-04-05 | 2013-04-09 | Alemtuzumab | Y | N | 310023341 | CVP R + GEMCITABINE |
| 310004723 | 310006889 | null | 65 | Curative (C) | 2015-09-09 | 2015-09-20 | Pazopanib | N | N | 310023341 | VINCRISTINE |
| 310004724 | 310006889 | 1.52 | 83 | Not known (9) | 2016-01-30 | 2016-02-01 | LANREOTIDE | 02 | N | 310023341 | CISPLATIN + FLUOROURACIL + RT |
| 310004725 | 310011672 | 1.84 | 68.4 | Not known (9) | 2016-02-24 | 2016-04-20 | Carboplatin + Pemetrexed | 2 | Y | 310023378 | CISPLATIN + DACARBAZINE |
| 310004726 | 310011672 | null | 39 | Curative (C) | 2015-05-04 | 2015-05-08 | IVE | 02 | N | 310023378 | BEVACIZUMAB |
| 310004727 | 310011876 | null | 0 | Palliative (P) | null | 2013-03-21 | METHOTREXATE | null | null | 310023395 | CYCLOPHOSPHAMIDE |
| 310004728 | 310002094 | 1.8 | 108 | Palliative (P) | 2015-03-04 | 2015-03-05 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 310023398 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 310004730 | 310002096 | 1.64 | 62.2 | Disease modification (D) | 2014-05-06 | 2014-05-06 | FEC 100 + DOCETAXEL | N | N | 310023403 | BEAM |
| 310004731 | 310006890 | null | 58.8 | Palliative (P) | null | 2016-07-10 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 310023407 | IVA |
| 310004732 | 310002097 | 1.62 | null | Palliative (P) | 2015-07-15 | 2015-07-15 | Trastuzumab Subcutaneous | null | null | 310023414 | FEC + DOCETAXEL |
| 310004733 | 310002098 | null | 70 | Adjuvant (A) | 2014-05-06 | 2014-05-07 | VINCRISTINE | N | N | 310023426 | CISPLATIN + PEMETREXED |
| 310004734 | 310002099 | 1.84 | 96.4 | Curative (C) | 2018-04-14 | 2018-05-02 | CTD Attenuated (Thalidomide 50mg) | Y | N | 310023441 | IVE |
| 310004736 | 310006891 | null | null | Not known (9) | 2015-06-07 | 2015-06-14 | CVP R | N | N | 310023468 | IVE |
| 310004737 | 310006891 | 1.8 | null | Palliative (P) | 2017-12-26 | 2018-01-09 | DABRAFENIB | N | Y | 310023468 | BRENTUXIMAB |
| 310004738 | 310006891 | 1.82 | 87 | Curative (C) | 2016-05-20 | 2016-05-20 | IVE + METHOTREXATE | N | N | 310023468 | DOXORUBICIN + IFOSFAMIDE |
| 310004739 | 310002101 | 1.8 | 74 | Palliative (P) | 2018-05-12 | 2018-05-12 | ECarboX | N | N | 310023481 | ABVD |
| 310004740 | 310002102 | 1.71 | 56.4 | Adjuvant (A) | 2018-05-30 | 2018-06-02 | Capecitabine + Cisplatin + RT | Y | Y | 310023489 | NHL 2003 |
| 310004741 | 310002103 | null | 99 | Palliative (P) | 2015-06-01 | 2015-06-08 | Cetuximab + Radiotherapy Load | 01 | N | 310023496 | BEP |
| 310004742 | 310002104 | 1.52 | null | Curative (C) | 2017-04-13 | 2017-04-13 | Bevacizumab 7.5mg/kg | 02 | N | 310023502 | BEVACIZUMAB |
| 310004743 | 310002104 | null | 81 | Disease modification (D) | 2015-10-06 | 2015-10-20 | Fluorouracil + Folinic Acid Weekly | 01 | Y | 310023502 | CAPECITABINE + CISPLATIN + RT |
| 310004744 | 310002105 | 1.58 | 57.5 | Curative (C) | 2014-07-01 | 2014-07-04 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 310023508 | SUNITINIB |
| 310004745 | 310002106 | 1.66 | null | Adjuvant (A) | 2017-04-13 | 2017-04-13 | RUXOLITINIB | 02 | null | 310023510 | FEC + DOCETAXEL |
| 310004746 | 310002107 | 1.72 | 52.9 | Adjuvant (A) | 2014-09-12 | 2014-09-27 | ICON8B TRIAL | N | N | 310023511 | DABRAFENIB + TRAMETINIB |
| 310004747 | 310002108 | 1.5 | 70 | Adjuvant (A) | 2016-07-23 | 2016-07-23 | FEC 100 | 2 | N | 310023518 | BEVACIZUMAB |
| 310004748 | 310002108 | 1.68 | 79.8 | Curative (C) | 2014-12-10 | 2015-01-16 | TEMOZOLOMIDE | N | N | 310023518 | CYTARABINE |
| 310004749 | 310002109 | 1.73 | null | Palliative (P) | 2017-08-05 | 2017-09-03 | GEMCITABINE + VINORELBINE | null | N | 310023536 | CYCLO + DOXORUBICIN + VINCRISTINE |
| 310004750 | 310006894 | 1.61 | 67.8 | Curative (C) | 2017-05-14 | 2017-05-17 | Gemcitabine + Oxaliplatin | null | N | 310023540 | CARBOPLATIN + PACLITAXEL + RT |
| 310004751 | 310002110 | 0 | 62.6 | Disease modification (D) | 2016-03-19 | 2016-03-20 | DABRAFENIB | N | N | 310023544 | BEVACIZUMAB |
| 310004752 | 310002111 | 1.85 | null | Adjuvant (A) | 2017-09-19 | 2017-09-28 | FCR | 02 | N | 310023575 | CARBOPLATIN + RT |
| 310004753 | 310002112 | 1.65 | 69.7 | Disease modification (D) | 2018-01-24 | 2018-01-26 | Cyclophosphamide Fludarabine (Oral) | 02 | N | 310023577 | CARBOPLATIN + RT |
| 310004754 | 310002113 | 1.64 | 77.8 | null | null | 2016-11-19 | CETUXIMAB | 02 | null | 310023581 | CISPLATIN + FLUOROURACIL + RT |
| 310004755 | 310002114 | 1.73 | 50 | Curative (C) | 2016-12-12 | 2016-12-12 | MITOMYCIN | N | N | 310023585 | CISPLATIN + DACARBAZINE |
| 310004756 | 310002114 | 1.49 | 59 | Curative (C) | 2014-07-25 | 2014-07-29 | ICON8B TRIAL | 02 | N | 310023585 | CARBOPLATIN + LIPOSOMAL DOX |
| 310004757 | 310002115 | 1.86 | 59.4 | Palliative (P) | 2015-11-05 | 2015-11-05 | Doxorubicin + Ifosfamide | N | null | 310023595 | DOXORUBICIN + IFOSFAMIDE |
| 310004758 | 310002116 | 1.7 | 101 | Curative (C) | 2014-11-08 | 2014-11-12 | CISPLATIN + GEMCITABINE + RITUXIMAB | 2 | N | 310023598 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 310004759 | 310002117 | null | null | Palliative (P) | 2013-06-24 | 2013-07-10 | CRIZOTINIB | 02 | N | 310023603 | INCA TRIAL |
| 310004760 | 310002118 | 1.8 | 50.5 | Curative (C) | 2015-08-25 | 2015-08-26 | POUT TRIAL | 2 | N | 310023609 | CISPLATIN + VINORELBINE + RT |
| 310004761 | 310002119 | null | 62 | Disease modification (D) | 2016-06-27 | 2016-06-27 | EC | 1 | N | 310023616 | BEVACIZUMAB + CARBO |
| 310004762 | 310002120 | 1.73 | 99.7 | Palliative (P) | null | 2015-11-02 | CYCLO + ETOPOSIDE + VINCRISTINE | N | N | 310023619 | BEVACIZUMAB |
| 310004763 | 310002121 | null | 77.3 | Palliative (P) | 2013-10-09 | 2013-10-10 | Epirubicin (weekly) | 02 | null | 310023620 | ALEMTUZUMAB |
| 310004764 | 310002121 | 1.79 | 91.2 | null | 2017-03-11 | 2017-03-14 | OCTREOTIDE | Y | null | 310023620 | IVE |
| 310004765 | 310002122 | 1.7 | 42.8 | Adjuvant (A) | 2016-10-09 | 2016-10-11 | Cytarabine Low Dose | 02 | N | 310023631 | CHLORAMBUCIL + ETOPOSIDE + LOMUSTINE |
| 310004767 | 310002124 | null | 50 | null | 2013-06-03 | 2013-06-26 | Lenalidomide 10mg (Cycle 1 to 25) | N | N | 310023645 | CYCLOPHOSPHAMIDE + GEMCITABINE + VINCRISTINE |
| 310004768 | 310002124 | null | 91.4 | Curative (C) | 2013-09-27 | 2013-10-10 | Carboplatin+Fluorouracil 4 or 5 day | N | null | 310023645 | CARBOPLATIN + LIPOSOMAL DOX |
| 310004770 | 310006898 | 1.74 | null | Palliative (P) | 2013-12-09 | 2013-12-20 | Trabectedin | 02 | N | 310023657 | HCX |
| 310004771 | 310002126 | 1.48 | 84.5 | Unknown (U) | 2015-10-15 | 2015-10-21 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA | 02 | N | 310023659 | ICON8B TRIAL |
| 310004772 | 310002126 | null | 20.2 | Disease modification (D) | 2013-11-01 | 2013-11-02 | Docetaxel 75mg/m2 (21 day) | N | N | 310023659 | BEVACIZUMAB + IRINOTECAN + MDG |